X chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutations

被引:10
作者
Allen, Christopher [1 ]
Lambert, Jonathan R. [1 ]
Linch, David C. [1 ]
Gale, Rosemary E. [1 ]
机构
[1] UCL, Inst Canc, Dept Haematol, London WC1E 6DD, England
基金
英国医学研究理事会;
关键词
STEM-CELL DISORDERS; ESSENTIAL THROMBOCYTHEMIA; MYELOPROLIFERATIVE NEOPLASMS; CLONALITY ANALYSIS; SOMATIC MUTATIONS; FEMALE-PATIENTS; V617F MUTATION; ALLELE BURDEN; HEMATOPOIESIS; COMPLICATIONS;
D O I
10.1182/blood-2014-06-580183
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Calreticulin mutations (CALR(MUT)) are found in a significant proportion of patients with essential thrombocythemia (ET) lacking JAK2(V617F) or MPL mutations. They are associated with substantially different hematological and clinical features and define a distinct subtype of ET. We show here that their presence is significantly correlated with a clonal X chromosome inactivation pattern (XCIP). Of 105 female ET patients investigated, 61 had an interpretable XCIP, and a clonal pattern was observed in 88% of CALR(MUT) patients compared with 26% of JAK2(V617F) (P =.0002) and 9% of JAK2(V617F) / MPL/CALR wild-type patients (P <.0001). Neutrophil CALR(MUT) level was significantly higher than JAK2(V617F) level (median, 50% vs 18%; P <.0001), and wild-type myelopoiesis was suppressed in CALR(MUT) but not JAK2(V617F) patients. These data are suggestive of truly monoclonal hematopoiesis in CALR(MUT) patients and provide further evidence that the biology associated with CALR mutations is markedly different from that of JAK2(V617F) mutations.
引用
收藏
页码:2091 / 2093
页数:3
相关论文
共 23 条
  • [1] Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
    Antonioli, E
    Guglielmelli, P
    Pancrazzi, A
    Bogani, C
    Verrucci, M
    Ponziani, V
    Longo, G
    Bosi, A
    Vannucchi, AM
    [J]. LEUKEMIA, 2005, 19 (10) : 1847 - 1849
  • [2] Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia
    Antonioli, Elisabetta
    Carobbio, Alessandra
    Pieri, Lisa
    Pancrazzi, Alessandro
    Guglielmelli, Paola
    Delaini, Federica
    Ponziani, Vanessa
    Bartalucci, Niccolo
    Tozzi, Lorenzo
    Bosi, Alberto
    Rambaldi, Alessandro
    Barbui, Tiziano
    Vannucchi, Alessandro M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (08): : 1435 - 1438
  • [3] MPL mutations in myeloproliferative disorders:: analysis of the PT-1 cohort
    Beer, Philip A.
    Campbell, Peter J.
    Scott, Linda M.
    Bench, Anthony J.
    Erber, Wendy N.
    Bareford, David
    Wilkins, Bridget S.
    Reilly, John T.
    Hasselbalch, Hans C.
    Bowman, Richard
    Wheatley, Keith
    Buck, Georgina
    Harrison, Claire N.
    Green, Anthony R.
    [J]. BLOOD, 2008, 112 (01) : 141 - 149
  • [4] Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones
    Beer, Philip A.
    Jones, Amy V.
    Bench, Anthony J.
    Goday-Fernandez, Andrea
    Boyd, Elaine M.
    Vaghela, Krishna J.
    Erber, Wendy N.
    Odeh, Bassam
    Wright, Christine
    McMullin, Mary Frances
    Cullis, Jonathan
    Huntly, Brian J. P.
    Harrison, Claire N.
    Cross, Nicholas C. P.
    Green, Anthony R.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (06) : 904 - 908
  • [5] Clonal hemapoiesis and risk of thrombosis in young female patients with essential thrombocythemia
    Chiusolo, P
    La Barbera, EO
    Laurenti, L
    Piccirillo, N
    Sorà, F
    Giordano, G
    Urbano, R
    Mazzucconi, MG
    De Stefano, V
    Leone, G
    Sica, S
    [J]. EXPERIMENTAL HEMATOLOGY, 2001, 29 (06) : 670 - 676
  • [6] Clonality analysis of hematopoiesis in essential thrombocythemia: Advantages of studying T lymphocytes and platelets
    ElKassar, N
    Hetet, G
    Briere, J
    Grandchamp, B
    [J]. BLOOD, 1997, 89 (01) : 128 - 134
  • [7] Gale RE, 1999, SEMIN HEMATOL, V36, P361
  • [8] Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years
    Gale, Rosemary E.
    Allen, Anthony J. R.
    Nash, Michael J.
    Linch, David C.
    [J]. BLOOD, 2007, 109 (03) : 1241 - 1243
  • [9] Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy
    Girodon, Francois
    Schaeffer, Celine
    Cleyrat, Cedric
    Mounier, Morgane
    Lafont, Ingrid
    Dos Santos, Frederic
    Vidal, Aurelie
    Maynadie, Marc
    Hermouet, Sylvie
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (11): : 1723 - 1727
  • [10] A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications
    Harrison, CN
    Gale, RE
    Machin, SJ
    Linch, DC
    [J]. BLOOD, 1999, 93 (02) : 417 - 424